VONWILLEBRAND DISEASE TYPE-B - A MISSENSE MUTATION SELECTIVELY ABOLISHES RISTOCETIN-INDUCED VONWILLEBRAND-FACTOR BINDING TO PLATELET GLYCOPROTEIN-IB

被引:86
作者
RABINOWITZ, I
TULEY, EA
MANCUSO, DJ
RANDI, AM
FIRKIN, BG
HOWARD, MA
SADLER, JE
机构
[1] WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,660 S EUCLID,BOX 8045,ST LOUIS,MO 63110
[2] WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110
[3] WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110
关键词
D O I
10.1073/pnas.89.20.9846
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
von Willebrand factor (vWF) is a multimeric glycoprotein that mediates the adhesion of platelets to the subendothelium by binding to platelet glycoprotein Ib. For human vWF, this interaction can be induced in vitro by the antibiotic ristocetin or the snake venom protein botrocetin. A missense mutation, Gly-561 --> Ser, was identified within the proposed glycoprotein Ib binding domain of vWF in the proband with von Willebrand disease type B, a unique variant characterized by no ristocetin-induced, but normal botrocetin-induced, binding to glycoprotein Ib. The corresponding mutant recombinant protein, rvWF(G561S), formed normal multimers and exhibited the same functional defect as the patient's plasma vWF, confirming that this mutation causes von Willebrand disease type B. These data show that botrocetin and ristocetin cofactor activities of vWF can be dissociated by a point mutation and confirm that these mediators promote vWF binding to platelets by different mechanisms. The normal botrocetin-induced binding and the defective ristocetin-induced binding of rvWF(G561S) suggest that the primary defect in von Willebrand disease type B may be a failure of normal allosteric regulation of the glycoprotein Ib binding function of vWF.
引用
收藏
页码:9846 / 9849
页数:4
相关论文
共 37 条
  • [21] EVIDENCE FOR A VONWILLEBRAND-FACTOR DEFECT IN FACTOR-VIII BINDING IN 3 MEMBERS OF A FAMILY PREVIOUSLY MISDIAGNOSED MILD HEMOPHILIA-A AND HEMOPHILIA-A CARRIERS - CONSEQUENCES FOR THERAPY AND GENETIC-COUNSELING
    MAZURIER, C
    GAUCHER, C
    JORIEUX, S
    PARQUETGERNEZ, A
    GOUDEMAND, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 (03) : 372 - 379
  • [22] MOHRI H, 1988, J BIOL CHEM, V263, P17901
  • [23] ENHANCED BOTROCETIN-INDUCED TYPE-IIB VONWILLEBRAND-FACTOR BINDING TO PLATELET GLYCOPROTEIN-IB INITIATES HYPERAGGLUTINATION OF NORMAL PLATELETS
    NISHIO, K
    FUJIMURA, Y
    NIINOMI, K
    TAKAHASHI, Y
    YOSHIOKA, A
    FUKUI, H
    USAMI, Y
    TITANI, K
    RUGGERI, ZM
    ZIMMERMAN, TS
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (04) : 261 - 266
  • [24] MULTIMERIC ANALYSIS OF VONWILLEBRAND-FACTOR BY MOLECULAR-SIEVING ELECTROPHORESIS IN SODIUM DODECYL-SULFATE AGAROSE-GEL
    RAINES, G
    AUMANN, H
    SYKES, S
    STREET, A
    [J]. THROMBOSIS RESEARCH, 1990, 60 (03) : 201 - 212
  • [25] MOLECULAR-BASIS OF VONWILLEBRAND DISEASE TYPE-IIB - CANDIDATE MUTATIONS CLUSTER IN ONE DISULFIDE LOOP BETWEEN PROPOSED PLATELET GLYCOPROTEIN-IB BINDING SEQUENCES
    RANDI, AM
    RABINOWITZ, I
    MANCUSO, DJ
    MANNUCCI, PM
    SADLER, JE
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (04) : 1220 - 1226
  • [26] VENOM COAGGLUTININ - ACTIVATOR OF PLATELET-AGGREGATION DEPENDENT ON VONWILLEBRAND FACTOR
    READ, MS
    SHERMER, RW
    BRINKHOUS, KM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (09) : 4514 - 4518
  • [27] RIBBA AS, 1991, BLOOD, V78, P1738
  • [28] RODEGHIERO F, 1987, BLOOD, V69, P454
  • [29] ROTH GJ, 1991, BLOOD, V77, P5
  • [30] PRIMER-DIRECTED ENZYMATIC AMPLIFICATION OF DNA WITH A THERMOSTABLE DNA-POLYMERASE
    SAIKI, RK
    GELFAND, DH
    STOFFEL, S
    SCHARF, SJ
    HIGUCHI, R
    HORN, GT
    MULLIS, KB
    ERLICH, HA
    [J]. SCIENCE, 1988, 239 (4839) : 487 - 491